Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Therapies for relapsing–remitting multiple sclerosis (RRMS) are only partially effective, and,
in most patients receiving such treatment, clinical activity persists. Accurately assessing the …

Over the last few decades, the improved diagnostic criteria, the wide use of MRI, and the
growing availability of effective pharmacologic treatments have led to substantial advances in …

BACKGROUND AND PURPOSE: Various authors have developed criteria to classify MR
imaging findings that suggest the possibility of multiple sclerosis. The purpose of this study was …

Natural history studies have identified factors that predict evolution to multiple sclerosis or risk
of disability accumulation over time. Although these studies are based on large multicentre …

Objective Many patients with multiple sclerosis (MS) are currently receiving treatment with
interferon (IFN)–β. Early identification of nonresponder patients is crucial to try different …

Background: As a symptom of multiple sclerosis (MS), fatigue is difficult to manage because
of its unknown etiology, the lack of efficacy of the drugs tested to date and the absence of …

Background and purpose Information regarding multiple sclerosis (MS) patients with the 2019
novel coronavirus disease (COVID‐19) is scarce. The study objective was to describe the …

Background: Awareness of the factors influencing discontinuation of immunomodulatory
drugs (IMD) treatment in multiple sclerosis (MS) can help to find approaches to patient …

Osteopontin (OPN) is a pleiotropic integrin binding protein with functions in cell-mediated
immunity, inflammation, tissue repair, and cell survival. Recent studies have shown that OPN …